GET DAILY SIGNALSWhy Is Journey Medical Corporation (DERM) Stock Down -1.59% Today?
Key Takeaways
- DERM slipped 1.59% to $4.32 in Friday morning trading, down from Thursday's close of $4.39.
- The primary driver is a third-quarter 2026 report that missed on both revenue and earnings, with growth decelerating sharply.
- A secondary driver is the fade of the after-hours relief rally that briefly lifted shares to $4.68 late Thursday.
- Sector drag: biotech is soft, with the XBI biotech ETF down about 1.6% intraday and small caps trading lower.
- Shares sit near the bottom of a 52-week range of $4.25 to $9.56 and have lost roughly 35% over the past three months.
- News Significance Score: 33/100 — Moderate earnings miss paired with a price move far smaller than the stock's typical swing.
- What to watch next: Emrosi prescription trends, 2027 formulary wins and the company's cash runway.
- Readers looking for deeper detail on valuation and expectations can review Price Targets, Earnings and the Forecast pages.
- To scan for AI-driven trading ideas across thousands of tickers, explore Trending AI Robots.
Opening Summary
Journey Medical Corporation (DERM) is a commercial-stage dermatology company based in Scottsdale, Arizona, that markets a portfolio of FDA-approved prescription brands for acne, rosacea and fungal infections; its growth story now rests largely on Emrosi, an oral rosacea treatment launched in 2025. In early trading Friday, the stock changed hands at $4.32, down 1.59% from Thursday's close of $4.39, moving lower. The immediate reason cited by the market is the company's third-quarter 2026 report, released after Thursday's close, which showed revenue and earnings below consensus and growth decelerating from earlier in the year.
Third-Quarter Results Miss on Both Lines
Journey Medical reported total revenue of $19.0 million, short of the roughly $20.5 million consensus, with net product sales up 11% year over year. The top line grew just 8%, a marked slowdown from 23% in the second quarter and 21% in the first. Emrosi generated $9.0 million in net sales, up 84% year over year, but sequential prescription growth cooled to about 8% from roughly 20% previously.
The quality of the print was mixed rather than poor. Gross margin improved to 69% from 67%, GAAP net loss narrowed to $1.3 million, or $0.05 per share, from $3.9 million a year earlier, and adjusted EBITDA reached $3.5 million, positive for a second straight quarter. A one-time $1.7 million vendor settlement inflated selling, general and administrative costs to $12.6 million, and that charge exceeded the entire GAAP net loss. Management also deferred the detailed financial guidance it had promised earlier in the year and signaled caution about guiding in the first half of 2027 — the element that most eroded investor confidence.
Relief Rally Fades as Cash Questions Return
Initial post-earnings positioning was constructive: shares rose as much as 6.6% shortly after the release, as investors focused on positive EBITDA and the pending access win. That bid did not survive the company's earnings call. Cash declined to $22.3 million from $24.1 million at year-end 2025, receivables climbed, $7.5 million of the term loan shifted into current liabilities, and risk disclosures continue to cite doubt about the ability to continue as a going concern alongside a possible need to raise capital. The stock opened Friday at $4.00, immediately retraced to $4.45, and has since settled near $4.32.
Analyst Backing Holds With a Trimmed Target
Covering analysts remain overwhelmingly constructive. Consensus stands at a Strong Buy among four analysts with an average 12-month target of $13.75, and one firm trimmed its target to $13 from $15 while keeping a Buy rating. Those targets imply substantial upside from current levels, but the direction of revisions is now downward, which likely reinforced rather than reversed the cautious tone.
Market Context and Trading Activity
The move is broadly aligned with the sector rather than exceptional for the stock. The XBI biotech ETF is down about 1.6% intraday after a 3.3% drop on Thursday, while the IWM small-cap ETF and the S&P 500 tracking SPY are off 0.4% and 0.3% respectively — so Journey Medical's decline is essentially in line with its sector. Opening activity was active but not a stampede, with roughly 18,000 shares changing hands in the first 20 minutes against average daily volume near 100,000 shares in recent months. Technically, the stock remains pinned near its 52-week low of $4.25 and well below its 200-day moving average, a pattern that has capped every rebound since September.
News Significance Score
A score of 0 would mean no meaningful news and an ordinary move for the stock; a score of 100 would mean transformative news plus an extreme, rare price move. This event scores 33 out of 100. The verified news is genuinely material for a company with a market capitalization near $124 million — a double miss, decelerating growth and deferred guidance — but it is an earnings miss rather than a binary regulatory or clinical event. The price response was unusually calm: the 1.59% decline is roughly half the stock's typical daily move of about 3.1%, and 40 of the past 60 sessions produced moves of equal or larger magnitude. Moderate news plus an unremarkable move combine into a mid-range score.
What Comes Next for DERM
Attention now turns to fourth-quarter and full-year 2026 results, expected in the first quarter of 2027, and to whether Emrosi prescriptions recover after the October softness tied to the higher copay bridge. The key scheduled catalyst is formulary coverage with the largest U.S. national health plan, covering more than 25 million lives, effective January 2027, though first-quarter deductible resets may delay the financial benefit. Investors will also watch for additional national and regional payer wins, progress toward consensus treatment guidelines, and any decision on guidance reinstatement. Principal risks include continued cash consumption, a dilutive financing, and the commercial momentum of a portfolio where legacy brands such as Qbrexza are contracting.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as conditions change. For readers who want to see which automated strategies are working right now, reviewing the Trending AI Robots page is a practical next step.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DERM's RSI Oscillator climbs out of oversold territory
The RSI Indicator for DERM moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for DERM just turned positive on November 11, 2026. Looking at past instances where DERM's MACD turned positive, the stock continued to rise in 48 of 53 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where DERM advanced for three days, in 232 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
DERM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DERM as a result. In 82 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 50-day moving average for DERM moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DERM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for DERM entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.929) is normal, around the industry mean (6.379). P/E Ratio (-20.318) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.865) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. DERM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DERM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement